
Paul R Harnett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/967089/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Whole–genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	27.8	1,206
2	Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research, 2009, 15, 1417-1427.	7.0	266
3	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
4	Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 4614-4618.	7.1	202
5	Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. European Journal of Echocardiography, 2011, 12, 945-952.	2.3	135
6	A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Annals of Oncology, 1998, 9, 1343-1345.	1.2	121
7	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	107
8	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 2012, 72, 4060-4073.	0.9	100
9	Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and <i>TP53</i> -Mutant Tumors and Identifies <i>NRAS</i> as an Oncogenic Driver. Clinical Cancer Research, 2014, 20, 6618-6630.	7.0	96
10	<i>ABCB1</i> (<i>MDR 1</i>) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical Cancer Research, 2008, 14, 5594-5601.	7.0	90
11	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1306-1315.	10.7	87
12	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 569-580.	7.0	79
13	Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 2005, 117, 1049-1054.	5.1	78
14	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
15	New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents. Critical Reviews in Oncology/Hematology, 2008, 67, 103-112.	4.4	69
16	Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLoS ONE, 2017, 12, e0175544.	2.5	64
17	Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. European Heart Journal Cardiovascular Imaging, 2013, 14, 228-234.	1.2	61
18	MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 2006, 100, 239-246.	1.4	58

#	Article	IF	CITATIONS
19	<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. Cancer Research, 2017, 77, 4268-4278.	0.9	56
20	Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. European Journal of Cancer, 2013, 49, 3396-3403.	2.8	54
21	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
22	Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. Cancer Genetics and Cytogenetics, 1991, 54, 109-113.	1.0	52
23	Expression of Progesterone Receptor A and B Isoforms in Low-grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 2004, 23, 138-144.	1.4	50
24	Home or Hospital? An Evaluation of the Costs, Preferences, and Outcomes of Domiciliary Chemotherapy. International Journal of Health Services, 2000, 30, 557-579.	2.5	49
25	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	7.0	47
26	Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. Journal of Circulating Biomarkers, 2018, 7, 184945441878261.	1.3	47
27	A comparison of two Quality-of-Life Questionnaires for cancer clinical trials: The Functional Living Index-Cancer (FLIC) and the Quality of Life Questionnaire Core module (QLQ-C30). Journal of Clinical Epidemiology, 1996, 49, 21-29.	5.0	44
28	Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 2001, 48, 229-234.	2.3	38
29	Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. Oncogene, 2015, 34, 485-495.	5.9	38
30	A costâ€utility approach to the use of 5â€fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Medical Journal of Australia, 1993, 158, 319-322.	1.7	37
31	Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PLoS ONE, 2011, 6, e17617.	2.5	36
32	A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Research and Treatment, 2017, 161, 63-72.	2.5	35
33	Carboplatin desensitization. Annals of Allergy, Asthma and Immunology, 2004, 93, 137-141.	1.0	33
34	Ankyrin Repeat Domain 1, <i>ANKRD1</i> , a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 2008, 14, 6924-6932.	7.0	33
35	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecologic Oncology, 2018, 150, 239-246.	1.4	32
36	Multidisciplinary teams and ICT: a qualitative study exploring the use of technology and its impact on multidisciplinary team meetings. BMC Health Services Research, 2018, 18, 444.	2.2	30

#	Article	IF	CITATIONS
37	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 2016, 7, 6353-6368.	1.8	29
38	Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting. British Journal of Cancer, 1990, 62, 23-27.	6.4	26
39	Scientists and clinicians test their metal–back to the future with platinum compounds. Lancet Oncology, The, 2002, 3, 312-318.	10.7	26
40	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 2013, 11, 189.	4.4	25
41	Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Annals of Oncology, 2014, 25, 160-165.	1.2	25
42	Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma. International Journal of Cancer, 1994, 59, 388-393.	5.1	24
43	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 2014, 4, 4669.	3.3	24
44	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecologic Oncology, 2004, 93, 417-421.	1.4	23
45	New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocrine-Related Cancer, 2022, 29, R1-R16.	3.1	23
46	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
47	Aminoglutethimide in Advanced Prostatic Carcinoma. British Journal of Urology, 1987, 59, 323-327.	0.1	21
48	Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 105-106.	3.8	19
49	<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precision Oncology, 2018, 2, 1-14.	3.0	19
50	Attitudes of health professionals to using routinely collected clinical data for performance feedback and personalised professional development. Medical Journal of Australia, 2019, 210, S17-S21.	1.7	19
51	Embedding continuous quality improvement processes in multidisciplinary teams in cancer care: exploring the boundaries between quality and implementation science. Australian Health Review, 2017, 41, 291.	1.1	18
52	Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. International Journal of Gynecological Cancer, 2007, 17, 359-366.	2.5	17
53	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. Gynecologic Oncology, 2016, 142, 458-464.	1.4	17
54	A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. Medical Journal of Australia, 2001, 174, 312-312.	1.7	16

#	Article	IF	CITATIONS
55	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	4.5	15
56	Developing an Intranet-Based Lymphedema Dashboard for Breast Cancer Multidisciplinary Teams: Design Research Study. Journal of Medical Internet Research, 2020, 22, e13188.	4.3	13
57	"But Doctor, What Have I Got to Lose ?― Journal of Clinical Oncology, 2001, 19, 3294-3296.	1.6	12
58	Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer. Social Science and Medicine, 2010, 71, 1548-1556.	3.8	12
59	Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982–2011. Cancer Epidemiology, 2016, 43, 15-21.	1.9	12
60	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors Journal of Clinical Oncology, 2018, 36, 48-48.	1.6	12
61	Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer, 2007, 17, 350-358.	2.5	11
62	A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety. BMC Medical Education, 2016, 16, 91.	2.4	11
63	A tool to improve the performance of multidisciplinary teams in cancer care. BMJ Open Quality, 2019, 8, e000435.	1.1	11
64	Integrated Multimodality Therapy for Embryonal Rhabdomyosarcoma of the Lower Genital Tract in Postpubertal Females. Gynecologic Oncology, 1998, 70, 141-146.	1.4	10
65	Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. European Journal of Cancer, 1996, 32, 2357-2359.	2.8	9
66	PRIMARY PERITONEAL CARCINOMA: A TREATABLE SUBSET OF PATIENTS WITH ADENOCARCINOMA OF UNKNOWN PRIMARY. ANZ Journal of Surgery, 1996, 66, 124-125.	0.7	8
67	Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and incisional vincristine, ifosfamide and epirubicin. Australian and New Zealand Journal of Medicine, 1998, 28, 400-402.	0.5	8
68	Adenocarcinoma of the Duodenum With Liver Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 305-306.	1.3	8
69	"But Doctor, What Have I Got to Lose ?". Journal of Clinical Oncology, 2003, 21, 27s-29.	1.6	8
70	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	2.8	8
71	Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 66-73.	1.1	6
72	Drug resistance in clinical practice: Patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1987, 23, 1601-1605.	0.7	5

#	Article	IF	CITATIONS
73	Orbital Metastasis from Prostatic Carcinoma. British Journal of Urology, 1987, 59, 591-592.	0.1	5
74	Heterogeneous repair of platinum-DNA adducts by protein extracts from mammalian tissues. Biochemical Pharmacology, 1994, 48, 1662-1665.	4.4	5
75	Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. European Journal of Cancer, 1995, 31, 1773-1777.	2.8	5
76	An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. JMIR Research Protocols, 2016, 5, e147.	1.0	5
77	Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. Mutation Research DNA Repair, 1998, 407, 243-252.	3.7	4
78	Choriocarcinoma of the lung masquerading as a persisting pregnancy of unknown location (<scp>PUL</scp>). Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 211-212.	1.0	3
79	The perils of a vanishing cohort: a study of social comparisons by women with advanced ovarian cancer. Psycho-Oncology, 2012, 21, 382-391.	2.3	3
80	Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to <scp>W</scp> estmead <scp>H</scp> ospital. Internal Medicine Journal, 2014, 44, 1235-1239.	0.8	3
81	Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. Scientific Reports, 2018, 8, 1508.	3.3	3
82	Improving Cancer MDT performance in Western Sydney – three years' experience. BMC Health Services Research, 2021, 21, 203.	2.2	3
83	Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. Cancers, 2021, 13, 3196.	3.7	3
84	Developing a maturity model for cancer multidisciplinary teams. International Journal of Medical Informatics, 2021, 156, 104610.	3.3	3
85	Cisplatin plus VP16-213 in advanced ovarian carcinoma. Gynecologic Oncology, 1988, 30, 159-162.	1.4	2
86	Adjuvant chemotherapy for node-positive breast cancer: a retrospective comparison of two different regimens of cyclophosphamide, methotrexate and 5-fluorouracil. Breast, 1999, 8, 28-34.	2.2	2
87	CARBOPLATIN DESENSITIZATION. Annals of Allergy, Asthma and Immunology, 2007, 99, 468-469.	1.0	2
88	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 680-688.	2.5	2
89	Managing quality in cancer services: why improvement isn't easy. Australian Health Review, 2005, 29, 406.	1.1	2
90	Vertebral osteomyelitis in advanced breast cancer. Australian and New Zealand Journal of Medicine, 1993, 23, 406-406.	0.5	1

#	Article	IF	CITATIONS
91	NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatology, 2013, 2013, 1-7.	0.9	1
92	Persisting elevation of alphafetoprotein after chemotherapy for germ cell tumour—not always due to viable malignancy?. European Journal of Cancer, 1995, 31, 1722.	2.8	0
93	I now wear a white coat. Medical Journal of Australia, 2001, 175, 228-228.	1.7	0
94	All pains are equal, but some seem more urgent than others. Lancet, The, 2012, 380, 28.	13.7	0
95	Beyond evidence: reappraising use of CAâ€125 as postâ€therapy surveillance for ovarian cancer. Medical Journal of Australia, 2012, 196, 440-441.	1.7	0
96	Carboplatin allergy and IgE regulation. Pathology, 2016, 48, S48.	0.6	0
97	Our Faustian pact with the digital world. Lancet Oncology, The, 2017, 18, 171-172.	10.7	0
98	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0
99	A cost–utility approach to the use of 5â€fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Medical Journal of Australia, 1993, 158, 866-866.	1.7	0
100	Genome-wide association study for identification of candidate SNPs associated with carboplatin and paclitaxel clearance in ovarian cancer patients Journal of Clinical Oncology, 2014, 32, 5563-5563.	1.6	0